Receptor-selective vasopressin analogs: a new push for "decatecholaminization"?

  title={Receptor-selective vasopressin analogs: a new push for "decatecholaminization"?},
  author={Peter Radermacher and Christoph Thiemermann},
  volume={39 6},
In this issue of Shock, Boucheix et al. have compared the effects of incremental doses of selepressin or arginine vasopressin (AVP) on systemic and coronary hemodynamics in healthy dogs (1). Selepressin (formerly known as FE202158), a relatively short-acting peptide analog of AVP, is a highly selective agonist at the vasopressin V1a receptor (2). The… CONTINUE READING